AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Millennium Management LLC

Millennium Management LLC cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 42.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 373,762 shares of the biotechnology company’s stock after selling 273,363 shares during the quarter. Millennium Management LLC owned 1.37% of AnaptysBio worth $9,366,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ANAB. First Light Asset Management LLC lifted its stake in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the period. Great Point Partners LLC boosted its holdings in AnaptysBio by 9.2% in the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after purchasing an additional 82,648 shares in the last quarter. Octagon Capital Advisors LP purchased a new stake in AnaptysBio in the 4th quarter valued at approximately $2,570,000. Fisher Asset Management LLC increased its position in AnaptysBio by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after purchasing an additional 500 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth approximately $38,000.

AnaptysBio Price Performance

ANAB stock opened at $32.35 on Wednesday. The company’s 50 day simple moving average is $35.37 and its 200-day simple moving average is $28.63. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31. The firm has a market capitalization of $883.77 million, a PE ratio of -5.27 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The company had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. As a group, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ANAB shares. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a report on Wednesday, August 14th. JPMorgan Chase & Co. increased their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.10.

Insider Buying and Selling

In other news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 33,940 shares of company stock worth $1,251,836. 33.70% of the stock is owned by corporate insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.